XFOR Insider Trading
Insider Ownership Percentage: 1.62%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $412,578.00
X4 Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at X4 Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
X4 Pharmaceuticals Share Price & Price History
Current Price: $4.35
Price Change: ▼ Price Decrease of -0.99 (-18.54%)
As of 04/29/2025 05:00 PM ET
X4 Pharmaceuticals Insider Trading History
X4 Pharmaceuticals Institutional Trading History
Data available starting January 2016
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Read More on X4 Pharmaceuticals
Volume
308,498 shs
Average Volume
90,272 shs
Market Capitalization
$755.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.58
Who are the company insiders with the largest holdings of X4 Pharmaceuticals?
X4 Pharmaceuticals' top insider shareholders include:
- Paula Ragan (CEO)
- Mary Dibiase (COO)
- Arthur Taveras (Insider)
- Tuvia Barlev (CEO)
- Murray Stewart (Insider)
- Mark Baldry (Insider)
- Adam S Mostafa (CFO)
- Michael S Wyzga (Director)
- Israel Niv (Director)
- Adam S Mostafa (CFO)
Learn More about top insider investors at X4 Pharmaceuticals.